APOC2
-
Official Full Name
apolipoprotein C-II
-
Overview
This gene encodes a lipid-binding protein belonging to the apolipoprotein gene family. The protein is secreted in plasma where it is a component of very low density lipoprotein. This protein activates the enzyme lipoprotein lipase, which hydrolyzes triglycerides and thus provides free fatty acids for cells. Mutations in this gene cause hyperlipoproteinemia type IB, characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis. This gene is present in a cluster with other related apolipoprotein genes on chromosome 19. Naturally occurring read-through transcription exists between this gene and the neighboring upstream apolipoprotein C-IV (APOC4) gene. [provided by RefSeq, Mar 2011] -
Synonyms
APOC2; apolipoprotein C-II; APO-CII; APOC-II; apolipoprotein C2;
- Recombinant Proteins
- Cell & Tissue Lysates
- Native Proteins
- Protein Pre-coupled Magnetic Beads
- Cynomolgus Monkey
- Guinea pig
- Horse
- Human
- Mouse
- Rat
- Rhesus Macaque
- E.coli
- E.Coli or Yeast
- HEK293
- HEK293T
- Human Plasma
- In Vitro Cell Free System
- Mammalian Cell
- Mammalian cells
- Wheat Germ
- C
- His
- Flag
- GST
- His (Fc)
- Avi
- His|GST
- His|T7
- SUMO
- Myc
- DDK
- MYC
- N/A
- N
- Involved Pathway
- Protein Function
- Interacting Protein
- APOC2 Related Research Area
APOC2 involved in several pathways and played different roles in them. We selected most pathways APOC2 participated on our site, such as Chylomicron-mediated lipid transport, HDL-mediated lipid transport, Lipid digestion, mobilization, and transport, which may be useful for your reference. Also, other proteins which involved in the same pathway with APOC2 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
Chylomicron-mediated lipid transport | APOA5;APOBB.1;APOA4B.1;APOC2;APOA4A;APOEA;APOEB;APOA4B.2;MTP |
HDL-mediated lipid transport | BMP1A;AMN;APOA1B;CETP;Alb;ABCA1;APOC2 |
Lipid digestion, mobilization, and transport | FABP11A;CLPS;APOBB.1;LMF1;LMF2;APOEB;FABP12;APOA4B.1;APOF |
Lipoprotein metabolism | Alb;APOC2;APOA4B.1;APOA5;APOF;APOA4A;LPA;ABCA1;MTP |
Metabolism | NFYBB;AKR1C21;NUBP2;HS3ST6;CEPT1A;CYP2K8;CYP3A5;LBR;NDUFAF7 |
Metabolism of lipids and lipoproteins | FABP12;NFYBA;CYP2Y3;ANKRD1;SREBF2;APOA4B.2;CYP2R1;SUMF2;CPNE7 |
Retinoid metabolism and transport | AKR1C4;RBP4;BCO2A;APOM;CLPS;APOA4B.1;APOA4A;RBP1;LRP12 |
Signal Transduction | GPR55A;PRICKLE1B;CCNT2B;OXGR1A.1;RHOV;RNF43;USP4;TAGAP1;FMNL1 |
APOC2 has several biochemical functions, for example, lipase inhibitor activity, lipid binding, lipoprotein lipase activator activity. Some of the functions are cooperated with other proteins, some of the functions could acted by APOC2 itself. We selected most functions APOC2 had, and list some proteins which have the same functions with APOC2. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
lipase inhibitor activity | FAF2;APOA1;APOC1;APOC3;APOC2;APOA2 |
lipid binding | SH3GL3;APOL4;FABP9;STARD6;Fert2;RUFY1;S1PR2;BPIFB3;BPIFA3 |
lipoprotein lipase activator activity | APOH;APOA5;APOC2 |
phospholipase activator activity | PDPK1;GM2A;APOC2;CCL3;CCL5;CCL8;ARHGAP6 |
phospholipase binding | APOC2;LMNB1;PRKCZ;CALM2;NEFL;DGKQ;WAS;CALM;CALM1 |
protein homodimerization activity | BOKB;ADRB3;TBX1;RELA;YARS2;NR2F2;HMGCR;GNPTG;JUP |
APOC2 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with APOC2 here. Most of them are supplied by our site. Hope this information will be useful for your research of APOC2.
d-mannose; APOE; APOA2; ALB; APOB
- Q&As
- Reviews
Q&As (24)
Ask a questionWithout functional APOC2 protein, the activation of lipoprotein lipase is compromised, leading to elevated levels of triglycerides in the blood, a condition known as hypertriglyceridemia.
Regular exercise has been shown to improve lipid metabolism and positively affect APOC2 protein activity, resulting in lower triglyceride levels in the blood.
Yes, mutations or deficiencies in the APOC2 gene can lead to various lipid metabolism disorders, including familial hypercholesterolemia and familial chylomicronemia syndrome.
Yes, variations or mutations in the APOC2 gene can affect the structure or function of the APOC2 protein, leading to altered lipid metabolism and potentially causing lipid-related disorders.
High-fat diets and excessive consumption of saturated fats are known to influence APOC2 protein activity and triglyceride levels in the body.
Yes, targeting APOC2 protein has been explored as a potential therapeutic strategy for the treatment of hypertriglyceridemia and related disorders. Inhibitors or modulators of APOC2 protein activity are currently under investigation.
Some natural compounds, such as omega-3 fatty acids and polyphenols found in certain foods, have been reported to modulate APOC2 protein activity and lipid metabolism. However, more research is required to fully understand their effects and establish appropriate dosage recommendations.
Currently, there are no medications specifically approved for targeting APOC2 protein. However, certain lipid-lowering medications, such as fibrates and omega-3 fatty acid supplements, indirectly affect APOC2 protein activity by modulating lipid metabolism.
Yes, APOC2 protein levels can be measured in blood samples using immunoassays.
Yes, genetic tests can be used to screen for mutations in the APOC2 gene, particularly in individuals with a family history of lipid metabolism disorders. These tests can help identify individuals at risk and guide treatment options.
Yes, researchers are studying the role of APOC2 in lipid metabolism disorders and exploring potential therapeutic strategies targeting this protein. Additionally, some studies are investigating the use of APOC2-modulating therapies for the treatment of hypertriglyceridemia.
APOC2 protein levels have been associated with increased risk of cardiovascular diseases, particularly hypertriglyceridemia-associated conditions. However, further research is needed to establish its utility as a reliable biomarker.
Apart from its role in lipid metabolism, the APOC2 protein has been implicated in inflammation, immune response, and cell proliferation processes, although further research is needed to fully understand these functions.
The potential side effects of APOC2-targeting therapies or interventions may vary depending on the specific treatment approach. However, some common side effects associated with lipid-lowering medications or interventions include gastrointestinal issues, muscle pain, liver problems, and allergic reactions. It is essential to consult with a healthcare professional for personalized information and guidance.
Yes, there are rare genetic disorders associated with APOC2 protein, such as familial chylomicronemia syndrome (FCS) and lipoprotein lipase deficiency (LPLD), which result in severe hypertriglyceridemia.
Yes, some medications, such as fibrates and omega-3 fatty acids, can help regulate APOC2 protein activity and reduce triglyceride levels in individuals with hypertriglyceridemia.
Studies have suggested a potential association between APOC2 protein and obesity, as higher levels of APOC2 have been observed in individuals with obesity, contributing to elevated triglyceride levels.
Elevated levels of triglycerides, caused by dysfunction of APOC2 protein, have been associated with an increased risk of cardiovascular diseases such as coronary artery disease and atherosclerosis.
APOC2 gene therapy is being explored as a potential treatment for certain lipid metabolism disorders, aiming to correct genetic mutations or deficiencies in the APOC2 gene and restore normal protein function. However, this approach is still in the experimental stages and requires further research.
There are several support groups and resources available for individuals and families affected by lipid metabolism disorders, including those associated with APOC2 abnormalities. These organizations provide information, advocacy, and support to help individuals navigate their conditions. Examples include the National Lipid Association and the National Organization for Rare Disorders (NORD).
The APOC2 protein is synthesized in the liver and intestine.
APOC2 protein interacts with various proteins and lipoproteins, including apolipoprotein C-III (APOC3) and apolipoprotein E (APOE), to regulate lipid metabolism and transport.
Yes, lifestyle modifications, including a healthy diet and regular physical activity, play a crucial role in managing APOC2-related disorders. These interventions can help control lipid levels and improve overall cardiovascular health. However, they may not be sufficient as standalone treatments, and medical interventions may be necessary in some cases.
APOC2 gene mutations are relatively rare in the general population. They are typically inherited in an autosomal recessive manner, meaning that individuals need to inherit mutated copies of the APOC2 gene from both parents to develop the associated disorders.
Customer Reviews (4)
Write a reviewThe APOC2 protein offered by the manufacturer exhibits exceptional quality and is precisely tailored to meet my experimental requirements.
Its purity, stability, and functionality make it an ideal choice for my research endeavors.
In addition to the remarkable quality of the protein, the manufacturer's support extends beyond the provision of the product itself.
With their meticulous documentation and support, I am confident that my utilization of APOC2 protein in clinical trials will meet all necessary regulations and guidelines.
Ask a Question for All APOC2 Products
Required fields are marked with *
My Review for All APOC2 Products
Required fields are marked with *